Health Protection Agency (HPA) has announced 464 additional cases of COVID-19.
The new cases mean that the total number of confirmed cases in the Maldives has now reached 29,052, since confirming the first case in March of last year.
According to HPA, the new cases include; 207 cases from the greater Male’ region, 146 cases from residential islands outside of Male’, and 14 cases from operational resorts, three from liveaboards, 1 from an island under development as well as 93 from industrial islands.
Out of the 146 cases confirmed from residential islands today, 38 cases are from the island of B. Eydhafushi, 28 cases are from K. Himmafushi, 19 cases are from Lh. Naifaru and 18 cases are from L. Gan.
The cases confirmed from industrial islands are three cases from Gulheefalhu, one case from Thilafushi and 89 cases from Maandhoo. The new cases are the highest that the Maldives has confirmed in a single day, since the beginning of the pandemic.
Meanwhile, 76 additional COVID-19 patients were confirmed to have made full recoveries over the last 24 hours, increasing total recoveries to 24,575. The Maldives now has 4,009 active cases. There are currently 122 patients in hospitals.
HPA added that the positive cases confirmed last night were from 3,948 samples (including repeated samples) tested for COVID-19.
73 COVID-19 patients have died from complications.
Health Protection Agency also announced that up until April 27, a total of 294,269 people in the Maldives have received the first dose of the COVID-19 vaccine while 92,612 people had received both doses.
According to the HPA, 840 received their first dose of the vaccine on April 27; 383 from Male' City and 457 from other residential islands.
Out of the 92,612 individuals who had received both shots of the vaccine, 3,963 were vaccinated on April 27. HPA stated that 1,417 were from Male' City while 2,546 were from other residential islands in the nation.
The Maldives is using the Astrazeneca-Oxford University developed vaccine as well as the Pfizer vaccine and the Sinopharm vaccine for the national vaccine program.